Emily Menendez

GU Oncology Now

A recent study published in <a href="https://www.clinical-genitourinary-cancer.com/article/S1558-7673(23)00040-X/fulltext" target="_blank" rel="noopener">Clinical Genitourinary Cancer</a> compared the activity of taxanes (TAX) with second-line androgen-receptor therapy (ART) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had been treated with first-line ART to find the optimal therapeutic sequence of mCRPC.The study evaluated 175 patients with chemotherapy-na&iuml;ve mCRPC who had been treated with first-line enzalutamide or abiraterone. Of the total number of patients, 69 (39%) and 30 (17%) were treated with second-line TAX or ART, respectively, while 76 (43%) patients did not receive further treatment. Progression-free survival (PFS) and overall survival (OS) were compared between the patients who were treated with second-line ART or TAX.At the start of first-line therapy, the median PFS and OS were 13 months and 34 months, respectively. No significant difference was found between enzalutamide or abiraterone. From the beginning of second-line therapy, the median PFS and OS were 6 months and 18 months, respectively. Compared with ART, docetaxel had significantly higher prostate-specific antigen (PSA, &ge;50%; 29% vs 0%; P&lt;.001) and radiological (21% vs 0%; P&lt;.001) responses.PFS was longer in patients who received TAX compared with those who received ART (6.7 months vs 4 months; hazard ratio, 0.63; 95% CI, 0.41-0.96; P=.034), but there was no significant difference in OS (19 months vs 12 months; P=.1). After propensity score adjustment, PFS (P=.2) and OS (P=.1) rates were similar in patients who received second-line TAX and ART.The study found that TAX provides higher PSA and radiological responses than ART overall in the second-line setting, but PFS and OS are similar. Further studies may help to determine the best treatment sequence for patients with mCRPC.

Second-line Treatment for mCRPC: Taxanes or Androgen Receptor Therapy?

Metastatic castration-resistant prostate cancer 

CRPC

A recent study published in Clinical Genitourinary Cancer compared the activity of taxanes with second-line androgen-receptor therapy for mCRPC.

Taxanes or Androgen Receptor Therapy for mCRPC?

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe